|Articles|April 13, 2022
Improving Titer, Quality and Efficiency of AAV Manufacturing and Production by Optimizing Osmolality
Author(s)Advanced Instruments
Modulating osmolality in the early stages of AAV1 upstream manufacturing, can result in improved outcomes such as overall yield, quality, reduced manufacturing costs and improved efficiencies.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
2
Generative AI and Adaptive Trials Shape Future Biotech Development
3
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
4
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
5